BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421, for Dry Eye Syndrome

BRIM Biotechnology, Inc. (“BRIM”), a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”), the world’s leading ophthalmic research organization for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). BRIM intends to initiate Phase 3 clinical studies with Ora’s support later this year.

Dotmatics supports Umicore Corporate R&D in processing of experimental data

N4 Pharma highlights potential of Nuvec® as gene therapy delivery platform

Gainwell Appoints Karen Shields as Chief Client Engagement Officer

VIDA Introduces New AI-Enabled Biomarker Services

New VIDA analysis packages & novel biomarkers empower trial sponsors to unlock breakthrough insights

BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca

BioIVT to Provide Rare Biosamples for the FNIH Biomarkers Consortium Neurodegenerative Disease Project

BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration.

Source the Best PseudoUridines at Industry-Renowned Exhibitions

BOC Sciences has prepared a long list of first-rate pseudoUridines to be presented at two industry-renowned exhibitions—CPhI North America and TIDES USA 2022. With only a few days away, BOC Sciences sincerely invites all researchers concerned to pay a visit to its booths and have a constructive conversation with its knowledgeable experts.

Scale-Up Facilities and Leading Expertise Drive Commercial Fermentation Progress

BOC Sciences provides high-quality antibiotics, bioactive by-products, enzyme inhibitors, mycotoxins, and other fermented products as well as comprehensive CDMO services.

ArisGlobal Acquires Boehringer Ingelheim’s Signal Analytics Technology

ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment As a part of the LifeSphere® platform, this solution will be named LifeSphere Clarity and will unlock crucial data patterns leveraging machine learning Rapid, robust benefit-risk assessment is key for all organizations collecting and processing large safety data sets Intelligent tool will drive industry-wide advancement of pharmacovigilance and patient safety capabilities

Biofourmis Selected by American College of Cardiology as Exclusive Virtual Care Platform to Drive TRANSFORM3 Study Focused on Closing Practice Gaps for Heart Conditions

The American College of Cardiology (ACC) is leveraging Biofourmis’ AI-based predictive analytics platform and virtual health navigators for ACC’s TRANSFORM(3) study. The study—which focuses on underserved populations with a history of healthcare disparities—will evaluate different intervention strategies for improving adherence to guideline-directed medication therapy (GDMT) for managing specific chronic cardiovascular conditions.

SeekGene Increases Efficiency by 500% by Leveraging MemVerge Memory Machine in the Cloud

SeekGene, a biotechnology research firm focusing on single-cell technology, has significantly reduced processing time and cost for data intensive single-cell analysis tasks using MemVerge Memory Machine running on AliCloud i4p compute instances. As a result, SeekGene is able to cut analytical time and costs significantly while optimizing their single-cell sequencing capabilities for researchers worldwide to promote faster development of precision medicine.

Absolute Antibody to be featured on “World’s Greatest!...” television series

NEWS RELEASE: Emmes launches Advantage eClinical

Please find below the latest news story from Emmes (CRO) announcing the launch of its Advanatge eClinical as a standalone cloud native clinical technology platform – after more than two years in development. Unusually, the new platform will be available to both Emmes and non-Emmes customers and aims to increase access to a suitable platform particularly for smaller biotechs. Should you have any questions or would like to run a Q&A around this news, please do let me know.

Biolog Announces New Leadership Team and Secures Major Investment to Drive Widespread Adoption of Industry-Leading Microbial Identification and Phenotypic Profiling Products

Biolog has appointed a new leadership team and secured a major investment to help drive widespread adoption of its industry-leading microbial identification and phenotypic profiling products

Domainex appoints Dr Scott Martin as Analytical and Bioanalytical Group Leader

Domainex Ltd, a leading integrated medicines research services partner, is pleased to announce that Dr Scott Martin has been appointed Analytical and Bioanalytical Group Leader with immediate effect.

Global CRO to Showcase Respiratory Expertise at 2022 ATS International Conference

Rho, a global full-service contract research organization (CRO), will showcase its expertise in pulmonary and respiratory related illnesses with attendees during the 2022 American Thoracic Society (ATS) International Conference, taking place at the Moscone Center in San Francisco, May 13-18. Rho experts will be at booth #2203 to share their knowledge of the latest advances in the rapidly evolving field of pulmonary medicine, some of which include asthma, COPD and cystic fibrosis. They will be available for one-on-one interviews during the conference with those interested in learning more about Rho’s industry developments.

Dotmatics Biology Solution for Antibody Discovery streamlines data collection and workflows to accelerate antibody research and therapies

Beacon Biosignals announces partnership with Stratus to advance at-home brain monitoring and machine learning-enabled neurodiagnostics

Beacon Biosignals, which applies AI to EEG to unlock precision medicine for brain conditions, today announced a partnership with Stratus, the nation’s leading provider of EEG services, to enable expanded clinical trial service capabilities by leveraging Beacon’s machine learning neuroanalytics platform.

physIQ Announces Two New Appointments to Executive Leadership Team to Advance Digital Health Market Commercialization

A leader in digital medicine, physIQ today announced the appointment of two new members to its executive leadership team to accelerate the organization’s commercialization strategy and growth trajectory. John Wilson has been named Senior Vice President and General Manager of Life Sciences, and Chris Englerth joins the team as Vice President of Marketing.